Cargando…
Precision Dosing Priority Criteria: Drug, Disease, and Patient Population Variables
The administered dose of a drug modulates whether patients will experience optimal effectiveness, toxicity including death, or no effect at all. Dosing is particularly important for diseases and/or drugs where the drug can decrease severe morbidity or prolong life. Likewise, dosing is important wher...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7188913/ https://www.ncbi.nlm.nih.gov/pubmed/32390828 http://dx.doi.org/10.3389/fphar.2020.00420 |
_version_ | 1783527395308863488 |
---|---|
author | Tyson, Rachel J. Park, Christine C. Powell, J. Robert Patterson, J. Herbert Weiner, Daniel Watkins, Paul B. Gonzalez, Daniel |
author_facet | Tyson, Rachel J. Park, Christine C. Powell, J. Robert Patterson, J. Herbert Weiner, Daniel Watkins, Paul B. Gonzalez, Daniel |
author_sort | Tyson, Rachel J. |
collection | PubMed |
description | The administered dose of a drug modulates whether patients will experience optimal effectiveness, toxicity including death, or no effect at all. Dosing is particularly important for diseases and/or drugs where the drug can decrease severe morbidity or prolong life. Likewise, dosing is important where the drug can cause death or severe morbidity. Since we believe there are many examples where more precise dosing could benefit patients, it is worthwhile to consider how to prioritize drug–disease targets. One key consideration is the quality of information available from which more precise dosing recommendations can be constructed. When a new more precise dosing scheme is created and differs significantly from the approved label, it is important to consider the level of proof necessary to either change the label and/or change clinical practice. The cost and effort needed to provide this proof should also be considered in prioritizing drug–disease precision dosing targets. Although precision dosing is being promoted and has great promise, it is underutilized in many drugs and disease states. Therefore, we believe it is important to consider how more precise dosing is going to be delivered to high priority patients in a timely manner. If better dosing schemes do not change clinical practice resulting in better patient outcomes, then what is the use? This review paper discusses variables to consider when prioritizing precision dosing candidates while highlighting key examples of precision dosing that have been successfully used to improve patient care. |
format | Online Article Text |
id | pubmed-7188913 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-71889132020-05-08 Precision Dosing Priority Criteria: Drug, Disease, and Patient Population Variables Tyson, Rachel J. Park, Christine C. Powell, J. Robert Patterson, J. Herbert Weiner, Daniel Watkins, Paul B. Gonzalez, Daniel Front Pharmacol Pharmacology The administered dose of a drug modulates whether patients will experience optimal effectiveness, toxicity including death, or no effect at all. Dosing is particularly important for diseases and/or drugs where the drug can decrease severe morbidity or prolong life. Likewise, dosing is important where the drug can cause death or severe morbidity. Since we believe there are many examples where more precise dosing could benefit patients, it is worthwhile to consider how to prioritize drug–disease targets. One key consideration is the quality of information available from which more precise dosing recommendations can be constructed. When a new more precise dosing scheme is created and differs significantly from the approved label, it is important to consider the level of proof necessary to either change the label and/or change clinical practice. The cost and effort needed to provide this proof should also be considered in prioritizing drug–disease precision dosing targets. Although precision dosing is being promoted and has great promise, it is underutilized in many drugs and disease states. Therefore, we believe it is important to consider how more precise dosing is going to be delivered to high priority patients in a timely manner. If better dosing schemes do not change clinical practice resulting in better patient outcomes, then what is the use? This review paper discusses variables to consider when prioritizing precision dosing candidates while highlighting key examples of precision dosing that have been successfully used to improve patient care. Frontiers Media S.A. 2020-04-22 /pmc/articles/PMC7188913/ /pubmed/32390828 http://dx.doi.org/10.3389/fphar.2020.00420 Text en Copyright © 2020 Tyson, Park, Powell, Patterson, Weiner, Watkins and Gonzalez http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Tyson, Rachel J. Park, Christine C. Powell, J. Robert Patterson, J. Herbert Weiner, Daniel Watkins, Paul B. Gonzalez, Daniel Precision Dosing Priority Criteria: Drug, Disease, and Patient Population Variables |
title | Precision Dosing Priority Criteria: Drug, Disease, and Patient Population Variables |
title_full | Precision Dosing Priority Criteria: Drug, Disease, and Patient Population Variables |
title_fullStr | Precision Dosing Priority Criteria: Drug, Disease, and Patient Population Variables |
title_full_unstemmed | Precision Dosing Priority Criteria: Drug, Disease, and Patient Population Variables |
title_short | Precision Dosing Priority Criteria: Drug, Disease, and Patient Population Variables |
title_sort | precision dosing priority criteria: drug, disease, and patient population variables |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7188913/ https://www.ncbi.nlm.nih.gov/pubmed/32390828 http://dx.doi.org/10.3389/fphar.2020.00420 |
work_keys_str_mv | AT tysonrachelj precisiondosingprioritycriteriadrugdiseaseandpatientpopulationvariables AT parkchristinec precisiondosingprioritycriteriadrugdiseaseandpatientpopulationvariables AT powelljrobert precisiondosingprioritycriteriadrugdiseaseandpatientpopulationvariables AT pattersonjherbert precisiondosingprioritycriteriadrugdiseaseandpatientpopulationvariables AT weinerdaniel precisiondosingprioritycriteriadrugdiseaseandpatientpopulationvariables AT watkinspaulb precisiondosingprioritycriteriadrugdiseaseandpatientpopulationvariables AT gonzalezdaniel precisiondosingprioritycriteriadrugdiseaseandpatientpopulationvariables |